Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations

Pharmacogenetics

Volumn 6, Issue 2, 1996, Pages 159-176

  Fuhr, Uwe ^a   Rost, Karl Ludwig ^b   Engelhardt, Reinald ^a   Sachs, Michael ^a   Liermann, Dieter ^a   Belloc, C ^c   Beaune, Philippe ^c   Janezic, Susan ^d   Grant, Denis ^d   Meyer, Urs A ^e   Staib, A Horst ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e UNIVERSITY OF BASEL   (Switzerland)

Author keywords

caffeine; cytochrome P450; N acetyltransferase; phenotyping

Indexed keywords

ACETYLCYSTEINE; ACYLTRANSFERASE; BROMAZEPAM; CAFFEINE; CAPTOPRIL; CARBIMAZOLE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; ESTROGEN; ETILEFRINE; FLUOROURACIL; GEMFIBROZIL; GLIBENCLAMIDE; IRON; ISOSORBIDE DINITRATE; LACTULOSE; LIVER ENZYME; METHOTREXATE; METOPROLOL; MOLSIDOMINE; PARAXANTHINE; PENTOXIFYLLINE; PHENACETIN; RANITIDINE; SULFADIMIDINE; THEOPHYLLINE; THYROXINE; UNINDEXED DRUG; VERAPAMIL;

ACETYLATION; ACETYLATOR PHENOTYPE; ADULT; AGED; ARTICLE; BIOTRANSFORMATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMETHYLATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SALIVA LEVEL; DRUG URINE LEVEL; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; LIVER MICROSOME; MALE; ORAL DRUG ADMINISTRATION; PARTIAL HEPATECTOMY; PHENOTYPE; PRIORITY JOURNAL;

AGED; ARYLAMINE N-ACETYLTRANSFERASE; CAFFEINE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2E1; FEMALE; GENOTYPE; HUMANS; LIVER; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PHENOTYPE; SALIVA; THEOPHYLLINE;

EID: 0344840980     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199604000-00003     Document Type: Article

References (74)

1. Armitage P, Berry G. Statistical methods in medical research, 2nd edition, Oxford: Blackwell Scientific Publications, 1987: 305-307.
2. Arnaud MJ, Welsch C. Theophylline and caffeine metabolism in man. In: Rietbrock N, Woodcock BG, Staib AH, eds. Theophylline and other methylxanthines. Braunschweig: Vieweg Verlag, 1982: 135-148.
3. Beaune P, Kremers P, Letawe-Goujon F, Gielen JE. Monoclonal antibodies against human liver cytochrome P-450s. Biochem Pharmacol 1985: 34, 3547-3552.
4. Benet ZL, Williams RL. Design and optimization of dosage regimens: pharmacokinetic data. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's The pharmacological basis of therapeutics, 8th edition. New York: Pergamon Press, 1990: 1650-1735.
5. Berthou F, Ratanasavanh D, Alix D, Carlhant D, Riche C, Guillouzo A. Caffeine and theophylline metabolism in newborn and adult human hepatocytes: comparison with adult rat hepatocytes. Biochem Pharmacol 1988: 37, 3691-3700.
6. Berthou F, Flinois JP, Ratanasavanh D, Beaunne P, Riche C, Guillouzo A. Evidence for the involvement of several cytochromes P-450 in the first steps of caffeine metabolism by human liver microsomes. Drug Metabol Dispos 1991: 19, 561-567.
7. Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993: 45, 1211-1214.
8. PA (P-4501A2). the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 1989: 86, 7696-7700.
9. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, Teitel CH, Massengill JP, Lawsen MF, Kadlubar FF. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992: 2, 116-127.
10. Campbell ME, Spielberg SP, Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 1987: 42, 157-165.
11. Clarke SE, Ayrton AD, Chenery RJ. Characterization of the inhibition of P4501A2 by furafylline. Xenobiotica 1994: 24, 517-526.
12. Crofts F, Taioli E, Trachman J, Cosma GN, Currie D, Toniolo P, Garte SJ. Functional significance of different human CYP1A1 genotypes. Carcinogenesis 1994: 15, 2961-2963.
13. Drakoulis N, Cascorbi I, Brockmöller J, Gross CR, Roots I. Polymorphism in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3′-flanking region. Clin Investigator 1994: 72, 240-248.
14. El Mouelhi M, Didolkar MS, Elias EG, Guengerich FP, Kauffman FC. Hepatic drug-metabolizing enzymes in primary and secondary tumors of human liver. Cancer Res 1987: 47, 460-466.
15. Eugster HP, Probst M, Würgler FE, Senkstag C. Caffeine, estradiol, and progesterone interact with human CYP1A1 and CYP1A2 evidence from cDNA-directed expression in Saccharomyces cerevisiae. Drug Metabol Dispos 1993: 21, 43-49.
16. Fuhr U, Wolff T, Harder S, Schymanski P, Staib AH. Quinolone inhibition of cytochrome P-450-dependent caffeine metabolism in human liver microsomes. Drug Metabol Dispos 1990: 18, 1005-1010.
17. Fuhr U, Doehmer J, Battula N, Wölfel C, Kudla C, Keita Y, Staib AH. Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 enzymes. Biochem Pharmacol 1992a: 43, 225-235.
18. Fuhr U, Anders E-M, Mahr G, Sörgel F, Staib AH. Inhibitory potency of quinolone antibacterial agents on cytochrome P4501A2 activity in vivo and in vitro. Antimicrob Agents Chemother 1992b: 36, 942-948.
19. Fuhr U, Klittich K, Staib AH. Inhibitory effect of grapefruit juice and the active component naringenin on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol 1993: 35, 431-436.
20. Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics 1994: 4, 109-116.
21. Fuhr U, Schneider A, Sörgel F, Doehmer J. Kinetics of caffeine metabolism by mammalian cell lines expressing isolated human CYP1A1, CYP1A2, or CYP2E1. In: Bellward GD, ed. Abstracts of the 10th International Symposium on Microsomes and Drug Oxidation. Toronto, 1994: 244.
22. Gonzalez FJ, Idle JR. Pharmacogenetic phenotyping and genotyping. Present status and future potential. Clin Pharmacokin 1994: 26, 59-70.
23. Grant DM, Tang BK, Kalow W. Polymorphic N-acetylation of a caffeine metabolite. Clin Pharmacol Ther 1983: 33, 355-359.
24. Grant DM, Tang BK, Kalow W. A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol 1984: 17, 459-464.
25. Grant DM, Campbell ME, Tang BK, Kalow W. Biotransformation of caffeine by microsomes from human liver. Biochem Pharmacol 1987: 36, 1251-1260.
26. Grant DM, Mörike K, Eichelbaum M, Meyer UA. Acetylation pharmacogenetics: the slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J Clin Invest 1990: 85, 968-972.
27. Grant DM, Blum M, Meyer UA. Polymorphisms of N-acetyltransferase genes. Xenobiotica 1992: 22, 1073-1081.
28. Grant DM. Molecular genetics of acetyltransferases. In: Bellward GD, ed. Abstracts of the 10th International Symposium on Microsomes and Drug Oxidation, Toronto, 1994: 12-14.
29. Gu L, Gonzalez FJ, Kalow W, Tang BK. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by c-DNA expressed human CYP1A2 and CYP2E1. Pharmacogenetics 1992: 2, 73-77.
30. c Colloque de Pont-à-Mousson. Paris: John Libbey Eurotext, 1993: 349-354.
31. Hein DW, Rustan TD, Doll MA, Bucher KD, Ferguson RJ, Feng Y, Furman EJ, Gray K. Acetyl-transferases and susceptibility to chemicals. Toxicol Lett 1992: 64-65 Spec No. 123-130.
32. Heymsfield SB, Fulenwider T, Nordlinger B, Barlow R, Sones P, Kutner M. Accurate measurement of liver, kidney, and spleen volume and mass by computerized axial tomography. Ann Int Med 1979: 90, 185-187.
33. Hickman D, Sim E. N-acetyltransferase polymorphism comparison of phenotype and genotype in humans. Biochem Pharmacol 1991: 42, 1007-1014.
34. Hotta H, Hatanaka T, Tsutsui M, Gonzalez FJ, Ono S, Satoh T. Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. In: Bellward GD, ed. Abstracts of the 10th International Symposium on Microsomes and Drug Oxidation. Toronto, 1994: 485.
35. Ingelman-Sundberg M, Johansson I, Yin H, Terelius Y, Elisasson E, Clot P, Albano E. Ethanol-inducible cytochrome P4502E1: Genetic polymorphism, regulation and possible role in the etiology of alcohol-induced liver disease. Alcohol 1993: 10, 447-452.
36. Ioannides C, Parke DV. Induction of cytochrome P4501 as an indicator of potential chemical carcinogenesis. Drug Metabol Rev 1993: 25, 485-501.
37. Kadlubar FF, Talaska G, Butler MA, Teitel CH, Hassengill JP, Lang NP. Determination of carcinogenic arylamine N-oxidation phenotype in humans by analysis of caffeine urinary metabolites. In: Mendelsohn ML, Albertini RJ, eds. Mutation and the environment. Part B: Metabolism, testing methods, and chromosomes. New York: John Wiley & Sons, 1990: 107-114.
38. Kadlubar FF, Butler MA, Kaderlink KR, Chou HC, Lang NP. Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis. Environm Health Perspect 1992: 98, 69-74.
39. Kadlubar FF. Biochemical individuality and its implications for drug and carcinogen metabolism: Recent insights from acetyltransferase and cytochrome P4501A2 phenotyping and genotyping in humans. Drug Metab Rev 1994: 26, 37-46.
40. Kalow W, Tang BK. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 1991: 50, 508-519.
41. Kalow W, Tang BK. The use of caffeine for enzyme assays: A critical appraisal. Clin Pharmacol Ther 1993: 53, 503-514.
42. Kharasch ED, Thummel KE, Mhyre J, Lillibridge JH. Single-dose disulfiram inhibition of chlorzoxazone metabolism: A clinical probe for P4502E1. Clin Pharmacol Ther 1993: 53, 643-650.
43. Kroemer HK, Echizen H, Heidemann H, Eichelbaum M. Predictability of the in vivo metabolism of verapamil from in vitro data: Contribution of individual metabolic pathways and stereoselective aspects. J Pharmacol Exp Ther 1992: 260, 1052-1057.
44. Kroemer HK, Gautier JC, Beaune P, Henderson C, Wolf CR, Eichelbaum M. Identification of P450 enzymes involved in the metabolism of verapamil in humans. Naunyn-Schmiedebergs Arch Pharmacol 1993: 348, 332-337.
45. Landi MT, Bertazzi PA, Shields PG, Clark G, Lucier GW, Garte SJ, Cosma G, Caporaso NE. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics 1994: 4, 242-246.
46. Lang NP, Butler MA, Massengill J, Lawson M, Stotts RC, Hauer-Jensen M, Kadlubar FF. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol Biomarkers Prevention 1994: 3, 675-682.
47. Lemoine A, Gautier JC, Azoulay D, Kiffel L, Belloc C, Guengerich FP, Maurel P, Beaune P, Leroux JP. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol 1993: 43, 827-832.
48. Lucas D, Berthou F, Dreano Y, Lozach P, Volant A, Ménez JF. Comparison of levels of cytochromes P-450, CYP1A2, CYP2E1, and their related monooxygenase activities in human surgical liver samples. Alcohol Clin Exp Res 1993: 17, 900-905.
49. McDonagh JE, Nathan VV, Bonavia IC, Moyle GR, Tanner AR. Caffeine clearance by enzyme multiplied immunoassay technique: a simple, inexpensive, and useful indicator of liver function. Gut 1991: 32, 681-684.
50. McKinnon RA, Hall P de la M, Quattrochi LC, Tukey RH, McManus ME. Localization of CYP1A1 and CYP1A2 messenger RNA in normal human liver and hepatocellular cyrcinoma by in situ hybridization. Hepatology 1991: 14, 848-856.
51. Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, Gonzalez FJ, Coon MJ, Gunsalus IC, Gotoh O, Okuda K, Nebert DW. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993: 12, 1-51.
52. Patten CJ, Thomas PE, Guy RL, Lee M, Gonzalez FJ, Guengerich FP, Yang CS. Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. Chem Res Toxicol 1993: 6, 511-518.
53. Perrot N, Nalpas B, Yang CS, Beaune PH. Modulation of cytochrome P450 isozymes in human liver by ethanol and drug intake. Eur J Clin Invest 1989: 19, 549-599.
54. Pirmohamed M, Williams D, Madden S, Templeton E, Park BK. Metabolism and bioactivation of clozapine by human liver microsomes. J Pharmacol Exp Ther 1995: 272, 984-990.
55. Quattrochi LC, Vu T, Tukey RH. The human CYP1A2 gene and induction by 3-methylcholantrene. J Biol Chem 1994: 269, 6949-6954.
56. Ratanasavanh D, Beaune P, Morel F, Flinois JP, Guengerich FP, Guillouzo A. Intralobular distribution and quantitation of cytochrome P450 enzymes in human liver as a function of age. Hepatology 1991: 13, 1142-1151.
57. Rodriguez JW, Kirlin WG, Ferguson RJ, Doll MA, Gray K, Rustan TD, Lee ME, Kemp K, Urso P, Hein DW. Human acetylator genotype: Relationship to colorectal cancer incidence and arylamine N-acetyltransferase expression in colon cytosol. Arch Toxicol 1993: 67, 445-452.
58. Rost KL, Brösicke H, Heinemeyer G, Roots I. Specific and dose-dependent enzyme induction by omeprazole in human beings. Hepatology 1994: 20, 1204-1212.
59. Rost KL, Roots I. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios - coincidence with plasma clearance and breath test. Clin Pharmacol Ther 1994: 55, 402-411.
60. Sachs L. Angewandte Statistik, 7th edition. Berlin: Springer Verlag, 1992: 489-518.
61. Schweikl H, Taylor JA, Kitareewan S, Linko P, Nagorney D, Goldstein JA. Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics 1993: 3, 239-249.
62. Sesardic D, Boobis AR, Edwards RJ, Davies DS. A form of cytochrome P450 in man, orthologous to form d in rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 1988: 26, 363-372.
63. Shimada T, Iwasaki M, Martin MV, Guengerich FP. Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in salmonella typhimurium TA 1535/pSK1002. Cancer Res 1989: 49, 3218-3228.
64. Tang BK, Kadar D, Kalow W. An alternative test for acetylator phenotyping with caffeine. Clin Pharmacol Ther 1987: 42, 509-513.
65. Tang BK, Gonzalez FJ, Kalow W. Caffeine as marker of cytochrome P450 CYP2E1. In: Bellward GD, ed. Abstracts of the 10th International Symposium on Microsomes and Drug Oxidation. Toronto, 1994a: 496.
66. Tang BK, Zhou Y, Kadar D, Kalow W. Caffeine as a probe for CYP1A2 activity: Potential influence of renal factors on urinary phenotypic trait measurements. Pharmacogenetics 1994b: 4, 117-124.
67. Tarrus E, Cami J, Roberts DJ, Spickett RGW, Celdran E, Segura J. Accumulation of caffeine in healthy volunteers treated with furafylline. Br J Clin Pharmacol 1987: 23, 9-18.
68. Tassaneeyakul W, Mohamed Z, Birkett DJ, McManus ME, Verones ME, Tukey RH, Quattrochi LC, Gonzalez FJ, Miners JO. Caffeine as a probe for human cytochromes P450: validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics 1992: 2, 173-178.
69. Tassaneeyakul W, Birkett DJ, McManus ME, Verones ME, Tukey RH, Quattrochi LC, Gelboin HV, Miners JO. Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 1993: 265, 401-407.
70. Tassaneeyakul Wi, Birkett DJ, McManus ME, Tassaneeyakul Wo, Veronese ME, Andersson T, Tukey RH, Miners JO. Caffeine metabolism by human hepatic Cytochrome P450: contribution of 1A2, 2E1 and 3A isoforms. Biochem Pharmacol 1994a: 47, 1767-1776.
71. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Miners JO. Direct characterization of the selectivity of furafylline as an inhibitor of human cytochromc P450 1A1 and 1A2. Pharmacogenetics 1994b: 4, 281-284.
72. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, Raisys VA, Marsh CL, McVicar JP, Barr DM, Perkins JD, Carithers L Jr. Use of midazolom as a human cytochrome P450 3A probe: 1. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994: 271, 549-556.
73. Tucker GT, Rostami-Hodjegan A, Jackson PR. The determination of drug metabolising status in vivo: Pharmacokinetic and statistical issues. In: Pacifici GM, Fracchia C, ed. Advances in drug metabolism in man. Brussels/Luxembourg: European Commission ECSC-EC-EAEC, 1995: 35-55.
74. Weber WW, Hein DW. N-acetylation pharmacogenetics. Pharmacol Rev 1985: 37, 25-79.